Related Experiment Videos
Modulation of secretory processes of phagocytes by IX 207-887
J Schnyder1, P Cooper, A MacKenzie
1Sandoz Research Institute Berne Ltd., Berne, Switzerland.
Springer Seminars in Immunopathology
|January 1, 1993
Summary
IX 207-887 is a novel anti-inflammatory drug that effectively treats rheumatoid arthritis by inhibiting cytokine release from mononuclear cells and reducing neutrophil activity. This drug offers a new therapeutic approach to managing chronic inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Chronic inflammation involves mediators released by phagocytes, contributing to disease initiation and progression.
- Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and damage.
Purpose of the Study:
- To evaluate the efficacy of IX 207-887 as a novel antiarthritic drug.
- To investigate the mechanisms of action of IX 207-887 in inflammatory processes.
Main Methods:
- In vitro studies assessing cytokine release from mononuclear cells.
- Analysis of neutrophil function, including superoxide production and granule release, in response to N-formyl-Met-Leu-Phe stimulation.
- A double-blind, placebo-controlled clinical trial in patients with rheumatoid arthritis.
Main Results:
- IX 207-887 inhibited cytokine release from mononuclear cells at therapeutically relevant concentrations.
- The drug significantly reduced superoxide production and granule release in stimulated neutrophils.
- Clinical studies demonstrated IX 207-887 to be an effective slow-acting drug for rheumatoid arthritis.
Conclusions:
- IX 207-887 demonstrates anti-inflammatory properties by modulating key mediators in chronic inflammation.
- The drug's mechanism involves inhibiting cytokine release and neutrophil activation.
- IX 207-887 represents a promising therapeutic agent for managing rheumatoid arthritis.